The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 10, 2025

Filed:

Sep. 24, 2021
Applicant:

National Vaccine and Serum Institute(nvsi), Beijing, CN;

Inventors:

Qiming Li, Beijing, CN;

Yu Liang, Beijing, CN;

Jing Zhang, Beijing, CN;

Jiguo Su, Beijing, CN;

Zibo Han, Beijing, CN;

Shuai Shao, Beijing, CN;

Yanan Hou, Beijing, CN;

Hao Zhang, Beijing, CN;

Shi Chen, Beijing, CN;

Yuqin Jin, Beijing, CN;

Xuefeng Zhang, Beijing, CN;

Lifang Du, Beijing, CN;

JunWei Hou, Beijing, CN;

Zhijing Ma, Beijing, CN;

Zehua Lei, Beijing, CN;

Fan Zheng, Beijing, CN;

Fang Tang, Beijing, CN;

Zhaoming Liu, Beijing, CN;

Ning Liu, Beijing, CN;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/215 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/215 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01);
Abstract

The present invention provides a recombinant RBD trimer protein capable of simultaneously generating cross neutralization activity for various severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) epidemic strains. The RBD trimer protein is taken as an antigen and supplemented with an adjuvant to immunize an organism, so that a high-titer neutralizing antibody aiming at various SARS-COV-2 epidemic strains can be generated at the same time, and the antibody has a certain broad-spectrum property and can be used for treating and/or preventing SARS-COV-2 infection and/or coronavirus disease 2019.


Find Patent Forward Citations

Loading…